Sylvie Maubant

543 total citations
20 papers, 425 citations indexed

About

Sylvie Maubant is a scholar working on Molecular Biology, Oncology and Immunology and Allergy. According to data from OpenAlex, Sylvie Maubant has authored 20 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 6 papers in Immunology and Allergy. Recurrent topics in Sylvie Maubant's work include Cell Adhesion Molecules Research (6 papers), Wnt/β-catenin signaling in development and cancer (4 papers) and Platelet Disorders and Treatments (3 papers). Sylvie Maubant is often cited by papers focused on Cell Adhesion Molecules Research (6 papers), Wnt/β-catenin signaling in development and cancer (4 papers) and Platelet Disorders and Treatments (3 papers). Sylvie Maubant collaborates with scholars based in France, United States and Netherlands. Sylvie Maubant's co-authors include Pascal Gauduchon, Séverine Cruet-Hennequart, Cathy Staedel, José Luis, Shoukat Dedhar, Gordon C. Tucker, John A. Hickman, Françoise Perron‐Sierra, Patrick Casara and Ellen Van Obberghen‐Schilling and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Sylvie Maubant

19 papers receiving 421 citations

Peers

Countries citing papers authored by Sylvie Maubant

Since Specialization

Citations

This map shows the geographic impact of Sylvie Maubant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvie Maubant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvie Maubant more than expected).

Fields of papers citing papers by Sylvie Maubant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvie Maubant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvie Maubant. The network helps show where Sylvie Maubant may publish in the future.

Co-authorship network of co-authors of Sylvie Maubant

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvie Maubant. A scholar is included among the top collaborators of Sylvie Maubant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvie Maubant. Sylvie Maubant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Gut Microbiome Integration in Drug Discovery and Development of Small Molecules 2024 ·Drug Metabolism and Disposition ·Patrick Jimonet, Céline Druart, Stéphanie Blanquet‐Diot, Lilia Boucinha, Stephanie Schulz, Françoise Le Vacon, Sylvie Maubant, Sylvie Rabot, Tom Van de Wiele, Frank Schuren, Vincent Thomas, Bernard Walther, Michael Zimmermann	7
2	Abstract 1792: Engineered exosome- mediated STAT6 knockdown in tumor associated macrophages (TAMs) results in potent single agent activity in a hepatocellular carcinoma (HCC) model 2021 ·Cancer Research ·Sushrut Kamerkar, Charan Leng, Olga Burenkova, Su Chul Jang, Christine McCoy, Kelvin Zhang, William K. Dahlberg, (unknown), (unknown), Sylvie Maubant, Olivier Duchamp, Kyriakos D. Economides, Timothy Soos, Dalia Burzyn, Sriram Sathyanarayanan	4
3	Abstract 2258: Erymethionase (methionine-gamma-lyase encapsulated into red blood cells) potentiates anti-PD-1 therapy in TNBC syngeneic mouse model 2019 ·Cancer Research ·(unknown), Sylvie Maubant, Marie Nathalie LeBlanc, (unknown), (unknown), (unknown), Olivier Duchamp, Fabrice Viviani, Françoise Horand, Alexander Scheer, Vanessa Bourgeaux	4
4	Abstract 2258: Erymethionase (methionine-gamma-lyase encapsulated into red blood cells) potentiates anti-PD-1 therapy in TNBC syngeneic mouse model 2019 ·(unknown), Sylvie Maubant, (unknown), (unknown), (unknown), (unknown), Olivier Duchamp, Fabrice Viviani, Françoise Horand, Alexander Scheer, Vanessa Bourgeaux	4
5	LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers 2018 ·Oncotarget ·Sylvie Maubant, Tania Tahtouh, (unknown), Virginie Maire, Fariba Némati, Bruno Tesson, Mengliang Ye, Guillem Rigaill, (unknown), Aurélie Dumont, David Gentien, Bérengère Marty-Prouvost, Leanne de Koning, (unknown), Didier Decaudin, Francisco Cruzalegui, Gordon C. Tucker, Sergio Roman‐Roman, Thierry Dubois	20
6	Abstract 5010: Advantages in using orthotopic syngeneic tumor models to evaluate immune-based approaches for cancer treatment 2018 ·Cancer Research ·Sylvie Maubant, Philippe Slos, (unknown), Francis Bichat, Jean‐François Mirjolet	0
7	Abstract 2669: Antitumor activity of the CMP-001 (TLR9 agonist) alone or combined with immune modulators in syngeneic tumor models 2017 ·Cancer Research ·Francis Bichat, Sylvie Maubant, Jean‐François Mirjolet, Philippe Slos, Arthur Μ. Krieg, Aaron H. Morris	2
8	Transcriptome Analysis of Wnt3a-Treated Triple-Negative Breast Cancer Cells 2015 ·PLoS ONE ·Sylvie Maubant, Bruno Tesson, Virginie Maire, Mengliang Ye, Guillem Rigaill, David Gentien, Francisco Cruzalegui, Gordon C. Tucker, Sergio Roman‐Roman, Thierry Dubois	61
9	Abstract 41: The Wnt3a targetome in triple-negative breast cancer cell lines 2015 ·Cancer Research ·Sylvie Maubant, Bruno Tesson, Virginie Maire, Mengliang Ye, Guillem Rigaill, David Gentien, Francisco Cruzalegui, Gordon C. Tucker, Sergio Roman‐Roman, Thierry Dubois	2
10	Abstract B94: Efficacy of PD-1 - PD-L1 pathway disruptors in syngeneic models 2015 ·Molecular Cancer Therapeutics ·(unknown), Francis Bichat, (unknown), Xavier Tizon, (unknown), Sylvie Maubant, Jean‐François Mirjolet	1
11	Abstract 2764: The depletion of LRP5, unlike that of LRP6, promotes apoptosis in triple-negative breast cancer cells, making it an interesting therapeutic target 2014 ·Cancer Research ·Sylvie Maubant, Virginie Maire, Bruno Tesson, Fariba Némati, David Gentien, Bérengère Marty-Prouvost, Stéphane Depil, Francisco Cruzalegui, Gordon C. Tucker, Sergio Roman‐Roman, Thierry Dubois	1
12	Abstract 4373: LRP5: a potential therapeutic target in triple-negative breast cancer. 2013 ·Cancer Research ·Sylvie Maubant, Virginie Maire, Bruno Tesson, David Gentien, Bérengère Marty-Prouvost, Francisco Cruzalegui, Stéphane Depil, Gordon C. Tucker, Sergio Roman‐Roman, Thierry Dubois	1
13	Adjuvant Properties of Cytosine-Phosphate-Guanosine Oligodeoxynucleotide in Combination with Various Polycations in an Ovalbumin-Vaccine Model 2011 ·Nucleic Acid Therapeutics ·Sylvie Maubant, Claire Banissi, Samantha Beck, (unknown), Alain Carpentier	12
14	Cell surface overexpression of αvβ5 integrin impedes αvβ3‐mediated migration of the human ovarian adenocarcinoma cell line IGROV1 2006 ·Cell Biology International ·Sylvie Maubant, Johanne Leroy‐Dudal, Franck Carreiras, E. Deslandes, (unknown), Cathy Staedel, Pascal Gauduchon	2
15	Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells 2006 ·Blood ·Sylvie Maubant, (unknown), (unknown), Françoise Perron‐Sierra, Patrick Casara, John A. Hickman, Gordon C. Tucker, Ellen Van Obberghen‐Schilling	89
16	Expression of α V-associated integrin β subunits in epithelial ovarian cancer andits relation to prognosis in patients treated with platinum-based regimens 2005 ·The Histochemical Journal ·Sylvie Maubant, Séverine Cruet-Hennequart, Soizic Dutoit, Yves Denoux, H. Crouet, M. Henry‐Amar, Pascal Gauduchon	24
17	αv integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells 2003 ·Oncogene ·Séverine Cruet-Hennequart, Sylvie Maubant, José Luis, Pascal Gauduchon, Cathy Staedel, Shoukat Dedhar	121
18	Involvement of αvβ 3 integrin and disruption of endothelial fibronectin network during the adhesion of the human ovarian adenocarcinoma cell line IGROV1 on the human umbilical vein cell extracellular matrix 2002 ·International Journal of Cancer ·Franck Carreiras, Bénédicte Thiébot, Johanne Leroy‐Dudal, Sylvie Maubant, M Breton, (unknown)	22
19	[Integrins, cell response to anti-tumor agents and chemoresistance]. 2002 ·PubMed ·Sylvie Maubant, Cathy Staedel, Pascal Gauduchon	5
20	Altered adhesion properties and alpha v integrin expression in a cisplatin‐resistant human ovarian carcinoma cell line 2001 ·International Journal of Cancer ·Sylvie Maubant, Séverine Cruet-Hennequart, Laurent Poulain, Franck Carreiras, François Sichel, José Luis, Cathy Staedel, Pascal Gauduchon	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact